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products where more brands were available. The larger the brand premium, then the 
lower the market share of the premium brand. More multiple switchers were aged 
under 50 years (31%) than 70–79 years (20%). CONCLUSIONS: Multiple switches 
between SSRI brands occur in around one in four Australian Concessional patients 
and this has the potential to confuse some patients if not adequately monitored by 
prescribers and pharmacists. Switching rates increased where more brands are avail-
able on the PBS as well as in younger patients. 
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OBJECTIVES: The use of innovative antidepressants has been growing as many were 
introduced since 1990s. However, physician prescribing patterns in innovative antide-
pressants is unclear. This study disentangled the impacts of sociological factors, such as 
physician, patient, and health-care system factors, on the patterns and dynamics of 
adopting innovative antidepressants for major depressive disorder (MDD) in the US. 
METHODS: A retrospective 15-year cross-sectional study was conducted using the 
1993–2007 National Ambulatory Medical Care Survey representing 125,605,444 MDD 
patients. The Heckman two-step model was used to capture physician’s two-stage 
prescribing decision and to correct sample selection bias. First, logistic regression was 
applied to examine the impact of sociological factors on whether an antidepressant is 
prescribed. Second, multinomial logistic regression was used to capture physician choices 
of innovative versus.older antidepressants. RESULTS: A total of 71.22% MDD patients 
were prescribed an antidepressant. Physicians who were primary care physicians, non-
owner of health-care settings, practiced in Western and non-metropolitan areas, and 
had not seen patients before were more likely to prescribe innovative antidepressants 
(all P < 0.001. ) Patients who were younger, non-Hispanic, belong to HMOs, and took 
patient education were more likely to receive innovative antidepressants (all P < 0.001.) 
Trend analyses revealed that physicians who were owners of non-solo practice, practiced 
in Midwestern, Northeastern and metropolitan areas were decreasing likelihood of 
prescribing innovative antidepressants over time. Patients who were non-white, non-
black and non-Hispanic, and enrolled in Medicaid had increasing likelihood of receiving 
innovative antidepressants over time. CONCLUSIONS: The patterns of physician pre-
scribing innovative antidepressants for MDD patients in the United States varied with 
sociological factors. Patient characteristics, physicians characteristics, and health-care 
system factors had impacts on physician’s decision on choosing innovative antidepres-
sants. Prescribing patterns also varied over time. 
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HEALTH SCIENCE STUDENTS ATTITUDES TOWARD RESEARCH AND 
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OBJECTIVES: To assess the attitudes toward research of health science students and 
discuss its implications to teaching. Attitudes about research are important because they 
may inﬂ uence the quality of research. In particular, attitudes and beliefs about research 
can affect the extent to which they will develop useful critical thinking skills. Health 
science students usually tend to view research methods courses negatively. However, an 
understanding of these attitudes is necessary to help instructors facilitate the learning of 
research methodology, by enabling them to create more positive attitudes toward such 
courses. METHODS: The attitudes toward research of students of health sciences (n = 
79), Manipal University, were measured using the instrument: the Attitudes toward 
research scale –ATR (Papanasiou, 2005). The sample of the study consisted of students 
enrolled for a course on “Biostatistics, Research Methodology and Epidemiology.” The 
ATR consist of 32 items constituting ﬁ ve subscales: research usefulness, research anxiety, 
positive attitudes, relevance to life, difﬁ culty of research. Data was summarized by 
computing descriptive statistics. RESULTS: Students of health sciences scored more than 
70% of the maximum score on the subscales -research usefulness, positive attitudes and 
relevance to life. They scored less than 50% of the maximum score on subscales 
-research anxiety and difﬁ culty of research. Students expressed that estimating sample 
size, data analysis and interpretation are the most difﬁ cult aspects in research. CON-
CLUSIONS: To reduce the research anxiety and feeling of difﬁ culty, topics relating to 
statistics are to be taught in a simpler way. They should be provided practical experience 
through project work. Usefulness of the topics is to be emphasised through actual data 
analysis and interpretation relating to their ﬁ eld. 
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OBJECTIVES: This case study aims to evaluate the long-term utilization and safety 
of two biological agents- etanercept and adalimumab in treating Taiwanese rheuma-
toid arthritis (RA) patients. METHODS: This cohort study used a population-based 
claim-data from the Kaopin Division of Taiwanese National Health Insurance during 
March 2006 to June 2009. Adult RA outpatients were identiﬁ ed by diagnosis code, 
and followed from the ﬁ rst prescription date (index date) of biological agents up to 
two months after discontinuation (prescription stop for more than 30 days) or the 
end of study. Prescription continuation rate between two drugs was evaluated using 
Kaplane-Meier survival curves and compared by the log-rank test. The frequencies of 
infectious events for new users of biological agents were also collected and the odds 
ratios of infectious events comparing etanercept against adalimumab were evaluated 
by logistic regression. RESULTS: Of all, 190 new users (mean age 53.43 ± 11.61 years; 
83.68% female) were assessed. Most patients (70.53%) were prescribed biological 
agents in medical centers and 63.16% of them used etanercept. Total cumulative 
exposure time is 184.32 patient-years (145.86 patient-years in etanercept group, 38.46 
patient-years in adalimumab group). Overall continuation rate for biological agents 
is 78.06% after 1 year, 55.04% after 2 years. The median continuation time is 836 
days (95% CI 541, 972). Twenty-nine infectious events were detected; the most fre-
quent events are pneumonia (seven events) and tuberculosis (six events). Patients who 
treated by etanercept had more infectious events than patients treated with adalim-
umab (OR: 5.99; 95% CI 1.55, 40.00). CONCLUSIONS: This study demonstrated 
that only half RA patients sustained their original biological therapy for more than 2 
years. Furthermore, RA patients who treatd with etanercept acquired higher risk of 
infectious events. However, it is still necessary to further ﬁ nd out reasons for discon-
tinuation and to explore the causality between biological agents and infectious events. 
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OBJECTIVES: To evaluate the risk for gastrointestinal (GI) events and 
cardiovascular(CV) events in patients >60 years with knee osteoarthritis using 
tNSAIDs or coxibs users. METHODS: A hospital-based retrospective cohort study 
was applied. Data on prescription drug (NSAIDs, celecoxib, etoricoxib) was obtained 
from June 2004 to June 2007 were included if they were aged >60 years. Patients with 
a history of gastrointestinal disease or heart disease were excluded. RESULTS: A total 
12,591 prescriptions from 1030 patients, an average of four prescriptions/patient/year, 
were screened—3982 (31.6%) prescriptions were for NSAIDs, 4426 (35.2%) were for 
celecoxib, and 4183 (33.2%) were for etoricoxib. The most common traditional 
NSAID prescribed was meloxicam (24%). The mean age of cohort was 69.6 years, 
with the majority being female (74%). Comparing celecoxib with NSAID use in 
logistic regression analysis, patients who received celecoxib were signiﬁ cantly less 
likely to suffer GI events than those who received NSAIDs; OR = 0.36 (95% CI 
0.21–0.63, P = 0.00). Similarly, etoricoxib was less likely to cause GI events than 
NSAIDs; OR = 0.52 (95% CI 0.28–0.98, P = 0.04). Comparing to patients aged under 
60 years, patients aged >70 years had a signiﬁ cantly higher chance of developing GI 
events, OR = 1.79 (95% CI 1.13–2.4) for patients aged 70–80 years and 3.36 (95% 
CI 1.78–5.81) for those aged >80 years. Drug exposure time, signiﬁ cantly increased 
the GI risks. For CV event, there were only three signiﬁ cantly associated with CV 
events-female (OR = 0.29, 95% CI 0.16–0.59, P = 0.00), age > 80 years (OR = 2.98, 
95% CI 1.57–4.23, P = 0.00), and drug exposure time (OR = 1.05, 95% CI 1.02–1.54, 
P = 0.00). CONCLUSIONS: Incidence of GI and CV events was lower for coxibs than 
for NSAIDs and celecoxib had a lower incidence than etoricoxib. Patients with 
advanced age and higher drug exposure time had a signiﬁ cantly. 
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OBJECTIVES: To elucidate the relationship of the risk of refractures to compliance 
and persistence with bisphosphonate therapy in Taiwan. METHODS: We conducted 
a retrospective cohort study based on claims database of Taiwan’s National Health 
Insurance (NHI) between 2003–2006. The study subjects included all new users of 
bisphosphonates. Compliance was estimated using a medication possession ratio 
(MPR), calculated as the total days of supply divided by the number of days between 
the ﬁ rst and last dispensing plus the days of supply of the last dispensing. Persistence 
with bisphosphonate therapy was deﬁ ned as continuous use, allowing for a reﬁ ll gap 
of 30 days. RESULTS: The refracture rates of the osteoporosis patients increased with 
time. The refracture rate was 5.15%, 7.36%, and 8.49% at the ﬁ rst, second, and third 
years, respectively. The refracture rate of patients with over 80% compliance was 
signiﬁ cantly lower than those with a compliance below 80% (P < 0.05). The study 
found that nearly half of the patients were noncompliant with therapy (MPR < 80%) 
at as early as 3 months, and only around 30% of the patients were adherent at 1 year. 
The results also showed that the risk of refracture increased for patients with MPR < 
80%, non-persistence, older patients and patients with comorbidities such as rheuma-
toid arthritis, diabetes mellitus or dementia. Patients with concomitant statin medica-
tion tended to have signiﬁ cantly lower refracture risks than those without. 
CONCLUSIONS: From the study, the compliance and persistence of Taiwanese 
